5 Facts you should know about

Pulmonary arterial hypertension

Patients with unexplained exertional dyspnea, syncope, and/or signs of RV dysfunction should be assessed for suspected PAH

According to most guidelines, low- and intermediate-risk patients should receive ERA + PDE-5i combination therapy at diagnosis

Achieving low-risk status within 1 year of diagnosis leads to a better 5-year prognosis

Risk assessment should be done at diagnosis, and then at least once every 3 to 6 months

By conducting a formal risk calculation, you can identify when it’s time to escalate your patient’s treatment in accordance with today's treatment guidelines

See our full disease profile

Rare Cardiology News